Skip to main content

A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors

Open
  • Protocol code: ITCC-098
  • EudraCT code: 2021-002713-34
  • Research group: Childhood Cancer and Blood Disorders
  • Service: Pediatric Oncohematology
  • Principal investigator:  Sábado Álvarez, Constantino
  • Pathology: Tumors
  • Phase: Fase II
  • Status: Recruiting volunteers